Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis

被引：81

作者：

Lai, Tianwen ^{[1
,2
]}

Wang, Shaobin ^{[1
]}

Xu, Zhiwei ^{[1
]}

Zhang, Chao ^{[1
]}

Zhao, Yun ^{[1
]}

Hu, Yue ^{[1
]}

Cao, Chao ^{[1
]}

Ying, Songmin ^{[1
,4
]}

Chen, Zhihua ^{[1
]}

Li, Wen ^{[1
]}

Wu, Bin ^{[2
]}

Shen, Huahao ^{[1
,3
]}

机构：

[1] Zhejiang Univ, Sch Med, Inst Resp Dis, Dept Resp & Crit Care Med,Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China

[2] Guangdong Med Coll, Inst Resp Dis, Affiliated Hosp, Dept Resp & Crit Care Med, Zhanjiang, Peoples R China

[3] State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China

[4] Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310003, Zhejiang, Peoples R China

来源：

SCIENTIFIC REPORTS | 2015年 / 5卷

基金：

中国国家自然科学基金;

关键词：

QUALITY-OF-LIFE; ANTI-IGE ANTIBODY; ANTIIMMUNOGLOBULIN-E THERAPY; ADD-ON THERAPY; COST-EFFECTIVENESS; IMMUNOGLOBULIN-E; MODERATE; CHILDREN; TOLERABILITY; ADULTS;

D O I：

10.1038/srep08191

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs; >= 52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.

引用

页数：8

共 67 条

[11] The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [J].